19207031|t|Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.
19207031|a|AIMS: Several SNPs and a microsatellite cytosine-adenine repeat promoter polymorphism of the IGF-1 gene have been reported to be associated with circulating IGF-1 serum concentrations. Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients. The aim of this study was to test if the IGF-1 gene polymorphisms are associated with the GH-dose of GH-deficient adults. MATERIALS & METHODS: A total of nine tagging SNPs, five additionally selected SNPs and a cytosine-adenine repeat polymorphism were determined in 133 German adult patients (66 men, 67 women; mean age 45.4 years +/- 13.1 standard deviation; majority Caucasian) with GH-deficiency (GHD) of different origin, derived from the prospective Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. Patients received GH-treatment for 12 months with finished dose-titration of GH and centralized IGF-1 measurements. GH-dose after 1 year of treatment, IGF-1 concentrations, IGF-1-standard deviation score (SDS), the IGF-1:GH ratio and anthropometric data were analyzed by genotype. RESULTS: Except for rs1019731, which showed a significant difference of IGF-1-SDS by genotypes (p = 0.02), all polymorphisms showed no associations with the GH-doses, IGF-1 concentrations, IGF-1-SDS and IGF-1:GH ratio after adjusting for the confounding variables gender, age and BMI. CONCLUSION: IGF-1 gene polymorphisms were not associated with the responsiveness to exogenous GH in GHD. Therefore, genetic variations of the IGF-1 gene seem not to be major influencing factors of the GH-IGF-axis causing variable response to exogenous GH-treatment.
19207031	0	14	Growth hormone	GeneOrGeneProduct	2688
19207031	23	47	growth hormone-deficient	DiseaseOrPhenotypicFeature	D004393
19207031	78	83	IGF-1	GeneOrGeneProduct	3479
19207031	197	202	IGF-1	GeneOrGeneProduct	3479
19207031	261	266	IGF-1	GeneOrGeneProduct	3479
19207031	301	306	IGF-1	GeneOrGeneProduct	3479
19207031	381	395	growth hormone	GeneOrGeneProduct	2688
19207031	397	399	GH	GeneOrGeneProduct	2688
19207031	457	459	GH	GeneOrGeneProduct	2688
19207031	469	481	GH-deficient	DiseaseOrPhenotypicFeature	D004393
19207031	482	490	patients	OrganismTaxon	9606
19207031	533	538	IGF-1	GeneOrGeneProduct	3479
19207031	582	584	GH	GeneOrGeneProduct	2688
19207031	593	605	GH-deficient	DiseaseOrPhenotypicFeature	D004393
19207031	776	784	patients	OrganismTaxon	9606
19207031	789	792	men	OrganismTaxon	9606
19207031	797	802	women	OrganismTaxon	9606
19207031	878	891	GH-deficiency	DiseaseOrPhenotypicFeature	D004393
19207031	893	896	GHD	DiseaseOrPhenotypicFeature	D004393
19207031	1016	1024	Patients	OrganismTaxon	9606
19207031	1034	1036	GH	GeneOrGeneProduct	2688
19207031	1093	1095	GH	GeneOrGeneProduct	2688
19207031	1112	1117	IGF-1	GeneOrGeneProduct	3479
19207031	1132	1134	GH	GeneOrGeneProduct	2688
19207031	1167	1172	IGF-1	GeneOrGeneProduct	3479
19207031	1189	1194	IGF-1	GeneOrGeneProduct	3479
19207031	1231	1236	IGF-1	GeneOrGeneProduct	3479
19207031	1237	1239	GH	GeneOrGeneProduct	2688
19207031	1317	1326	rs1019731	SequenceVariant	rs1019731
19207031	1369	1374	IGF-1	GeneOrGeneProduct	3479
19207031	1454	1456	GH	GeneOrGeneProduct	2688
19207031	1464	1469	IGF-1	GeneOrGeneProduct	3479
19207031	1486	1491	IGF-1	GeneOrGeneProduct	3479
19207031	1500	1505	IGF-1	GeneOrGeneProduct	3479
19207031	1506	1508	GH	GeneOrGeneProduct	2688
19207031	1594	1599	IGF-1	GeneOrGeneProduct	3479
19207031	1676	1678	GH	GeneOrGeneProduct	2688
19207031	1682	1685	GHD	DiseaseOrPhenotypicFeature	D004393
19207031	1724	1729	IGF-1	GeneOrGeneProduct	3479
19207031	1783	1785	GH	GeneOrGeneProduct	2688
19207031	1786	1789	IGF	GeneOrGeneProduct	3479
19207031	1834	1836	GH	GeneOrGeneProduct	2688
19207031	Association	3479	2688	Novel
19207031	Negative_Correlation	2688	D004393	No